40 results found.

Melanoma (Skin) Clinical Trial using gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Identification of Genomic Lesions Promoting Nodal Metastasis in Malignant Melanoma.
gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Malignant Melanoma Clinical Trial using Zelboraf (vemurafenib)

Genentech - Recruiting 16 years or older.
- An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E.
Zelboraf (vemurafenib)

Malignant Melanoma Clinical Trial using DEDN6526A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma.
DEDN6526A

Malignant Melanoma Clinical Trial using MPDL3280A; Vemurafenib (Zelboraf®)

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma.
MPDL3280A; Vemurafenib (Zelboraf®)

Malignant Melanoma With Metastasis Clinical Trial using Vaccine consisting of a peptide derived from the protein IDO

Herlev Hospital - Recruiting 18 years to 80 years.
- Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man).
Vaccine consisting of a peptide derived from the protein IDO

Esophageal Cancer, Bile Duct Neoplasms, Gastric Cancer, Liver Can Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites..

Malignant Melanoma Clinical Trial using vemurafenib; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence.
vemurafenib; Placebo

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; acenocoumarol

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; acenocoumarol

Metastatic Cancers Other Than Melanoma That Express ESO Antigen, Clinical Trial using Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes.
Anti-NY ESO-1 mTCR PBL; Aldesleukin; Cyclophosphamide; Fludarabine

Breast Cancer, Colorectal Cancer, Gastric Cancer, Malignant Melan Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- OCCURRENCE RATE OF COLON CANCER, BREAST CANCER, GASTRIC CANCER AND MALIGNANT MELANOMA IN TURKEY & DIAGNOSIS AND TREATMENT CHARACTERISTICS.

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; tizanidine

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3- PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; tizanidine

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; phenprocoumon

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; phenprocoumon

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; digoxin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
vemurafenib; digoxin

Malignant Melanoma Clinical Trial using Observation

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- The High-Dose Aldesleukin (IL-2) 'SELECT' Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma.
Observation

Melanoma Clinical Trial using Ipilimumab; Stereotactic Ablative Radiosurgery (SART)

Comprehensive Cancer Centers of Nevada - Recruiting 18 years or older.
- Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma.
Ipilimumab; Stereotactic Ablative Radiosurgery (SART)

Melanoma Clinical Trial using Blood Draw

Comprehensive Cancer Centers of Nevada - Recruiting 18 years or older.
- Culture and Characterization of Circulating Tumor Cells (CTC) From Patients With Malignant Melanoma and Other Cancers.
Blood Draw

Malignant Melanoma Clinical Trial using Ipilimumab

Bristol-Myers Squibb - Recruiting 12 years to 17 years.
- Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma.
Ipilimumab

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

Malignant Melanoma Clinical Trial using Zelboraf

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa..
Zelboraf

Malignant Melanoma Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 12 years to 17 years.
- An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations.
vemurafenib

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; rifampin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib.
vemurafenib; rifampin

Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uv Clinical Trial using tumor specimens

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Clinical and Histopathologic Characteristics of BAP1 Mutations.
tumor specimens

Malignant Melanoma Clinical Trial using BMS-936558 (MDX1106-04); Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma.
BMS-936558 (MDX1106-04); Ipilimumab

Malignant Melanoma Clinical Trial using PegIFN alfa-2b

Merck Sharp & Dohme Corp. - Recruiting 20 years to 75 years.
- An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol No. MK-4031 370 Also Known as SCH 54031, P08556).
PegIFN alfa-2b

Malignant Melanoma Clinical Trial using vemurafenib; Placebo; GDC-0973 (cobimetinib)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 (COBIMETINIB) IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA.
vemurafenib; Placebo; GDC-0973 (cobimetinib)

Stage IV Melanoma Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; bevacizumab; ipilimumab; laboratory biomarker analysis; pharmacological study

Academic and Community Cancer Research United - Recruiting 18 years or older.
- Randomized Phase II Study of AB (AbraxaneT, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative).
paclitaxel albumin-stabilized nanoparticle formulation; bevacizumab; ipilimumab; laboratory biomarker analysis; pharmacological study

Melanoma (Skin) Clinical Trial using cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma.
cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

Melanoma (Skin) Clinical Trial using bevacizumab; oxaliplatin; sorafenib tosylate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma.
bevacizumab; oxaliplatin; sorafenib tosylate

Malignant Melanoma Clinical Trial using IMCgp100

Immunocore Ltd - Recruiting 18 years or older.
- A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma.
IMCgp100

Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm Clinical Trial using Alisertib; Pazopanib

University of Illinois at Chicago - Recruiting 18 years or older.
- Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors.
Alisertib; Pazopanib

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Malign Clinical Trial using magnetic resonance imaging with positron emission tomography scanning

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Evaluating Attenuation Correction Methods Applied to PET/MRI.
magnetic resonance imaging with positron emission tomography scanning

Malignant Melanoma Clinical Trial using SCIB1

Scancell Ltd - Recruiting 18 years or older.
- A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma.
SCIB1

Patients at Risk for Melanoma Clinical Trial using SAMScore questionnaire

Nantes University Hospital - Recruiting 18 years or older.
- COPARIME: Pilot Study of a Target Detection of Malignant Melanoma.
SAMScore questionnaire

Mucosal Lentiginous Melanoma, or Acral Lentiginous Malignant Mela Clinical Trial using nilotinib

Institute of Cancer Research, United Kingdom - Recruiting 18 years or older.
- A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma.
nilotinib

Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma Clinical Trial using Nilotinib

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification..
Nilotinib

Malignant Melanoma Clinical Trial using SentoCloner; Temodalr or Dacarbazine Medacr

SentoClone AB - Recruiting N/A or older.
- A Multi-centre, Two-arm, Randomized, Open, Phase II Study Investigating SentoCloner Compared to Reference Treatment in Advanced Malignant Melanoma.
SentoCloner; Temodalr or Dacarbazine Medacr

Malignant Melanoma Clinical Trial

Royal Marsden NHS Foundation Trust - Recruiting N/A or older.
- Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples.

Uveal Melanoma Clinical Trial using Hypofractionated linear accelerator radiotherapy

Medical University of Vienna - Recruiting 18 years or older.
- Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea.
Hypofractionated linear accelerator radiotherapy

Malignant Melanoma, Pancreatic Cancer, Colon Cancer, or Cervical Clinical Trial using Survivin peptide vaccine

Julius-Maximilians University - Recruiting 19 years to 90 years.
- Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides.
Survivin peptide vaccine